In a similar comprehensive study depicting genetic landscape of ccRCC by Sato Y et al, SETD2 and BAP1 mutations are likely to be acquired and selected from within pre-existing VHL- and/or PBRM1-mutated clones and contribute to tumour progression18. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.